Medewerkers
After completing my master Nanobiology, I have joined the Radiobiology of radionuclide therapy group in the Erasmus MC for my PhD. My project focusses on investigating the radiobiological effects of treatment with various radionuclides on 2D liver and prostate cancer cells. Furthermore, we will investigate the influence of an hypoxic environment on the radiobiological effects of radionuclide treatment. Amongst others, we evaluate the overall radiation sensitivity and DNA repair capacity of the cells. I really enjoy working on this project because it bridges between fundamental research and clinical applications.
Although I originally studied computer science, I ended up doing a PhD in bioinformatics at the Evolutionary Biology Institute in Barcelona, and I did a postdoc on aging transcriptomics at Erasmus MC. During my postdoc I started collaborating with Julie Nonnekens' group on the RNA analysis of the cell's response to TRT. I am very happy to have joined the UNRANU project, where I will lead the bioinformatic analyses of several experiments.
I have a background in biotechnology and cancer biology, with a PhD focused on fundamental DNA repair mechanisms. In 2014, I joined Erasmus MC and entered the exciting field of nuclear medicine, where I now lead a research group studying the radiobiology of radionuclide therapy. I enjoy working in multidisciplinary teams, and UNRANU exemplifies how collaboration across fields can accelerate innovation and improve patient outcomes.
After my master Chemistry at Leiden University, I am very happy to have joined the Applied Radiation and Isotopes group in Delft for my PhD. My research focusses on developing a generator for Ho-166, which is a promising nuclide for theragnostic applications. I am excited to be part of this interdisciplinary consortium, because my chemical research benefits greatly from having the perspective of biologists, companies and patients already in an early stage.
I am an imaging physicist working at TU Delft. My research focuses on improving imaging technologies such as SPECT, PET and CT by designing new scanner geometries and improving image reconstruction algorithms. I am excited to join such an interdisciplinary consortium as it allows me to better understand what problems are encountered in practice and which technologies can ultimately benefit patients.
I am a PhD candidate at TU Delft with a background that combines nuclear physics and biomedical imaging. My research focuses on preclinical SPECT and CT imaging to advance radionuclide therapy. I enjoy working at the interface of physics and medicine, developing innovative collimator designs and image reconstruction methods that are essential for accurate characterization of radioactive distribution and achieving more effective cancer treatment.
I am a chemist by training with a strong interest in applying chemistry to health-related challenges. After completing my master’s degree in chemistry at the University of Cape Town (South Africa), I pursued a PhD in molecular and radiochemistry through a joint program between Chimie ParisTech, PSL Université (Paris, France) and SCK CEN (Mol, Belgium). During this time, I discovered the exciting and evolving field of radiochemistry while working on the development of Re-188 radiopharmaceuticals. I completed my PhD in December 2024 and began a postdoctoral position at Radboudumc in April 2025 within the UNRANU project. I’m excited to contribute to this highly collaborative environment by developing novel Ho‑166 microspheres for radioembolization and exploring ways to better understand the effects of radiation on cancer.
With a background in Physics, I joined the Nuclear Medicine group at Radboud UMC for my PhD under the supervision of Frank Nijsen, Sandra Heskamp, Mark Konijnenberg and Giulia Tamborino. My project focuses on the dosimetry of targeted radionuclide therapy in cancer. More precisely, I am developing computational models to calculate absorbed doses in 2D and 3D for in-vitro and in-vivo experiments, enabling comparison between different radionuclides. As part of a multidisciplinary consortium, I particularly value collaborating with biologists and companies, since this exchange deepens our understanding and supports the translation of research into clinical applications.